Uterine cervical cancer
Conditions
Interventions
Introduce alendronate and vitamin D at the initiation of radiation therapy for cervical cancer.
Sponsors
Kobe University Graduate School of Medicine, Division of Radiation Oncology
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1)Female whose age is 45 year or more or postmenopause 2)Diagnosed with osteoporosis 3)Candidate for definitive radiation therapy for cervical cancer 4)ECOG Performance status < 2
Exclusion criteria
Exclusion criteria: 1)Patients with esophageal disorder 2)Patients who cannot sit upright for 30 minuites 3)Patients with a history of allergy to bisphosphonate or vitamin D 4)Patients with hypocalcemia who need treatment 5)Patients with severely impaired renal function (serum creatinine >1.5mg/dL) 6)Patients with severely impaired liver or heart function 7)Patients who were treated with antiosteoporotic medication 8)Patients who are planned to undergo intensity modulated radiation therapy 9)Patients who are considered to be inappropriate by the physician
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| 1.The incidence of symptomatic insufficiency fracture after definitive radiation therapy (RT) in patients with cervical cancer who are prescribed with alendronate and vitamin D. 2.The change of bone density after the RT. 3.The change of bone metabolism markers after the RT. 4.The adverese effect of alendronate and vitamin D. | — |
Primary
| Measure | Time frame |
|---|---|
| The incidence of insufficiency fracture after definitive radiation therapy in patients with cervical cancer who are prescribed with alendronate and vitamin D. | — |
Countries
Japan
Contacts
Public ContactMiyawaki Daisuke
Kobe University Hospital Radiation Oncology
Outcome results
None listed